BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Soriano JB, Lucas SJ, Jones R, Miravitlles M, Carter V, Small I, Price D, Mahadeva R; Respiratory Effectiveness Group. Trends of testing for and diagnosis of α1-antitrypsin deficiency in the UK: more testing is needed. Eur Respir J 2018;52:1800360. [PMID: 29853490 DOI: 10.1183/13993003.00360-2018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Crossley D, Stockley R, Sapey E. Alpha-1 Antitrypsin Deficiency and Accelerated Aging: A New Model for an Old Disease? Drugs Aging 2019;36:823-40. [PMID: 31179525 DOI: 10.1007/s40266-019-00684-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Miravitlles M, Nuñez A, Torres-durán M, Casas-maldonado F, Rodríguez-hermosa JL, López-campos JL, Calle M, Rodríguez E, Esquinas C, Barrecheguren M. The Importance of Reference Centers and Registries for Rare Diseases: The Example of Alpha-1 Antitrypsin Deficiency. COPD: Journal of Chronic Obstructive Pulmonary Disease 2020;17:346-54. [DOI: 10.1080/15412555.2020.1795824] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Soriano JB; all co-authors. Challenges in interpreting trends in testing for α1-antitrypsin deficiency in COPD patients from UK primary care. Eur Respir J 2018;52:1802064. [PMID: 30573694 DOI: 10.1183/13993003.02064-2018] [Reference Citation Analysis]
4 van Dijk M, Gan CT, Koster TD, Wijkstra PJ, Slebos DJ, Kerstjens HAM, van der Vaart H, Duiverman ML. Treatment of severe stable COPD: the multidimensional approach of treatable traits. ERJ Open Res 2020;6:00322-2019. [PMID: 32984420 DOI: 10.1183/23120541.00322-2019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
5 Morales DR. Challenges in interpreting trends in testing for α1-antitrypsin deficiency in COPD patients from UK primary care. Eur Respir J 2018;52:1801986. [PMID: 30573693 DOI: 10.1183/13993003.01986-2018] [Reference Citation Analysis]
6 Belmonte I, Nuñez A, Barrecheguren M, Esquinas C, Pons M, López-Martínez RM, Ruiz G, Blanco-Grau A, Ferrer R, Genescà J, Miravitlles M, Rodríguez-Frías F. Trends in Diagnosis of Alpha-1 Antitrypsin Deficiency Between 2015 and 2019 in a Reference Laboratory. Int J Chron Obstruct Pulmon Dis 2020;15:2421-31. [PMID: 33116457 DOI: 10.2147/COPD.S269641] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Estey MP, Tahooni T, Nelson TN, Parker ML, Agbor TA, Yang HM, Jen R, Barakauskas VE, Lam GY, Matthews A, Mattman A. Is the diagnostic rate for the common subtypes of A1AT deficiency consistent across two Canadian Provinces? Clin Biochem 2021;95:84-8. [PMID: 33964271 DOI: 10.1016/j.clinbiochem.2021.05.002] [Reference Citation Analysis]
8 Sieloff EM, Rutledge B, Huffman C, Vos D, Melgar T. National trends and outcomes of genetically inherited non-alcoholic chronic liver disease in the USA: estimates from the National Inpatient Sample (NIS) database. Gastroenterol Rep (Oxf) 2021;9:38-48. [PMID: 33747525 DOI: 10.1093/gastro/goaa091] [Reference Citation Analysis]
9 Chorostowska-Wynimko J, Barrecheguren M, Ferrarotti I, Greulich T, Sandhaus RA, Campos M. New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency. Int J Chron Obstruct Pulmon Dis 2020;15:345-55. [PMID: 32103933 DOI: 10.2147/COPD.S234646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
10 Scarlata S, Santangelo S, Ferrarotti I, Corsico AG, Ottaviani S, Finamore P, Fontana D, Miravitlles M, Incalzi RA. Electrophoretic α 1 -globulin for screening of α 1 -antitrypsin deficient variants. Clinical Chemistry and Laboratory Medicine (CCLM) 2020;58:1837-45. [DOI: 10.1515/cclm-2020-0071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Quinn M, Ellis P, Pye A, Turner AM. Obstacles to Early Diagnosis and Treatment of Alpha-1 Antitrypsin Deficiency: Current Perspectives. Ther Clin Risk Manag 2020;16:1243-55. [PMID: 33364772 DOI: 10.2147/TCRM.S234377] [Reference Citation Analysis]
12 Dummer J, Dobler CC, Holmes M, Chambers D, Yang IA, Parkin L, Smith S, Wark P, Dev A, Hodge S, Dabscheck E, Gooi J, Samuel S, Knowles S, Holland AE. Diagnosis and treatment of lung disease associated with alpha one-antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand. Respirology 2020;25:321-35. [PMID: 32030868 DOI: 10.1111/resp.13774] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]